Results 231 to 240 of about 294,834 (247)

Anaphylaxis-Associated Cerebral Infarction: A Case Report. [PDF]

Cureus
Watanabe T, Yamana H, Ishigami K, Tsutsumi Y, Kato N.   +4 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Clinical application of the HALP score for predicting early neurological deterioration in older patients with acute cerebral infarction. [PDF]

Biomed Rep
Lin YJ, Guo AB, Huang MM, Liang X, Xie Y, Li LL.   +5 more
europepmc   +1 more source

Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?

British Journal of Pharmacology, EarlyView.
Psychedelic drugs that activate 5‐HT2A receptors have been long used for cultural, medicinal and recreational purposes. Interest in psychedelics for treating psychiatric disorders has resurged recently and is well documented; less well recognised are their anti‐inflammatory properties. Growing evidence now demonstrates that psychedelics modulate immune
Omar Qureshi, Jamie Cowley, Ashley Pegg, Alison J. Cooper, John Gordon, Catherine A. Brady, Antonio Belli, Sam Butterworth, Rachel Upthegrove, Nick Andrews, Nicholas M. Barnes   +10 more
wiley   +1 more source

Retraction Note: Effects of the TLR4 signaling pathway on apoptosis of neuronal cells in diabetes mellitus complicated with cerebral infarction in a rat model. [PDF]

Sci Rep
Li C, Che LH, Ji TF, Shi L, Yu JL.
europepmc   +1 more source

Frontline ATRA‐ATO Therapy for Acute Promyelocytic Leukemia in Japan: Results From the Prospective Multicenter FBMTG‐APL2017 Trial

Cancer Science, EarlyView.
FBMTG‐APL2017: First prospective multicenter trial evaluating frontline ATRA‐ATO therapy for newly diagnosed APL in Japan, encompassing both low–intermediate (n = 65) and high‐risk (n = 16) patients. Excellent outcomes (95% CR, 94% 3‐year DFS) with comparable efficacy between risk groups (DFS: 97% vs.
Ken Takase, Tomohiko Kamimura, Takuro Kuriyama, Takahito Tokuyama, Hideho Henzan, Yoshikane Kikushige, Ilseung Choi, Yutaka Imamura, Akio Mori, Shuki Ohya, Noriaki Kawano, Koji Yonemoto, Mine Harada, Koichi Akashi, Toshihiro Miyamoto   +14 more
wiley   +1 more source

Predicting ICU Readmission in Patients With Cerebral Infarction: A Machine Learning Approach Using Neurophysiological and Clinical Data. [PDF]

Brain Behav
Su H, Huang X, Xiao Y, Xu X, Yu S, Cao Q.   +5 more
europepmc   +1 more source

Predictive Value of Substance P for Pulmonary Infection in Patients With Acute Cerebral Infarction During Hospitalization. [PDF]

J Clin Neurol
Jiang L, Yuan Q, Guo X, Zhou B, Zhang Y, Li L, Yan C, Zhang Y, Ma Y.   +8 more
europepmc   +1 more source

Simultaneous Stain with Neutral Red and Tetrazolium Salt for Experimental Cerebral Infarction Morphometry.

, 1992
Seo Jh, Park Yk, Kim Mh, Chong Yg, Chung Hs, Suh Jk, Lee Hk, Chu Jw, K C Lee   +8 more
openalex   +1 more source

Flow Diverter Implantation for Intracranial Aneurysm with Concomitant Cerebral Infarction in the Chronic Phase: A 3-Year Complete Obliteration Case. [PDF]

Am J Case Rep
Huang LX, Wu XB, Wang H, Wang SW, Luo B.
europepmc   +1 more source